Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population
The management of dementia in Alzheimer's disease has dramatically changed since the development of anti‐dementia drugs. However, there is limited information available regarding the bio‐medical aspects of the differing drugs; particularly relating to adults with intellectual disability. Indeed...
Gespeichert in:
| Veröffentlicht in: | International journal of geriatric psychiatry 2004-06, Vol.19 (6), p.509-515 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 515 |
|---|---|
| container_issue | 6 |
| container_start_page | 509 |
| container_title | International journal of geriatric psychiatry |
| container_volume | 19 |
| creator | Prasher, V. P. |
| description | The management of dementia in Alzheimer's disease has dramatically changed since the development of anti‐dementia drugs. However, there is limited information available regarding the bio‐medical aspects of the differing drugs; particularly relating to adults with intellectual disability. Indeed the information available for the intellectual disabled population is limited to adults with Down syndrome. This review highlights the important pharmacological and clinical aspects of donepezil, rivastigmine, galantamine and memantine and supports the view that such drugs play an important part in the management of dementia in adults with intellectual disability. Future clinical and research issues are discussed. Copyright © 2004 John Wiley & Sons, Ltd. |
| doi_str_mv | 10.1002/gps.1077 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66643087</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21111410</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5067-48c0e81a88d14e4fc929cda35d2b8bea14771ecc1a591c139f3cba6a3437e6dc3</originalsourceid><addsrcrecordid>eNqN0stu1DAUBuAIgehQkHgC5A2XRQN2bnbYlQID0nArICQ21olzMuPiOMF2OkxfkNci6USFDYKFZR_7029LPlF0l9HHjNLkybr344Lza9GC0bKMGSuK69GCCpHHRZLSg-iW92eUjmdM3IwOWJ6wcfBF9PMUzzVuSdeQurPY44U2R8Tpc_BBr1tt8YiswYANMBUEbE1abMd6qprOkbBBEhxCaNGGyxycVhqItuTYXGxQt-geelJrj-Bx2oZ6MMGTrQ4b8rzbWuJ3tnZdi0-JbnujFQTdWX-Vr21AY1CFAcyUA5U2OuxI3_WDubS3oxsNGI935vkw-vzyxaeTV_Hq3fL1yfEqVjkteJwJRVEwEKJmGWaNKpNS1ZDmdVKJCoFlnDNUikFeMsXSsklVBQWkWcqxqFV6GD3Y5_au-z6gD7LVXo2PA4vd4GVRFFlKBf8nnD5AMM7-BzKWMTrCR3uoXOe9w0b2TrfgdpJRObWBHNtATm0w0ntz5lC1WP-G87-P4P4MwCswjQOrtP_DibxM82J08d5ttcHdXy-Uy_cf54tnr33AH1ce3DdZ8JTn8svbpfx6-ky8-bAqZZL-AodL3Us</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21111410</pqid></control><display><type>article</type><title>Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Prasher, V. P.</creator><creatorcontrib>Prasher, V. P.</creatorcontrib><description>The management of dementia in Alzheimer's disease has dramatically changed since the development of anti‐dementia drugs. However, there is limited information available regarding the bio‐medical aspects of the differing drugs; particularly relating to adults with intellectual disability. Indeed the information available for the intellectual disabled population is limited to adults with Down syndrome. This review highlights the important pharmacological and clinical aspects of donepezil, rivastigmine, galantamine and memantine and supports the view that such drugs play an important part in the management of dementia in adults with intellectual disability. Future clinical and research issues are discussed. Copyright © 2004 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0885-6230</identifier><identifier>EISSN: 1099-1166</identifier><identifier>DOI: 10.1002/gps.1077</identifier><identifier>PMID: 15211527</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Alzheimer Disease - drug therapy ; Biological and medical sciences ; Carbamates - therapeutic use ; Cholinesterase Inhibitors - therapeutic use ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; dementia ; donepezil ; Down syndrome ; Down Syndrome - complications ; galantamine ; Galantamine - therapeutic use ; Geriatrics ; Humans ; Indans - therapeutic use ; learning disability ; Medical sciences ; memantine ; Memantine - therapeutic use ; mental retardation ; Neurology ; Nootropic Agents - therapeutic use ; Phenylcarbamates ; Piperidines - therapeutic use ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Rivastigmine</subject><ispartof>International journal of geriatric psychiatry, 2004-06, Vol.19 (6), p.509-515</ispartof><rights>Copyright © 2004 John Wiley & Sons, Ltd.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5067-48c0e81a88d14e4fc929cda35d2b8bea14771ecc1a591c139f3cba6a3437e6dc3</citedby><cites>FETCH-LOGICAL-c5067-48c0e81a88d14e4fc929cda35d2b8bea14771ecc1a591c139f3cba6a3437e6dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fgps.1077$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fgps.1077$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15859356$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15211527$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Prasher, V. P.</creatorcontrib><title>Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population</title><title>International journal of geriatric psychiatry</title><addtitle>Int. J. Geriat. Psychiatry</addtitle><description>The management of dementia in Alzheimer's disease has dramatically changed since the development of anti‐dementia drugs. However, there is limited information available regarding the bio‐medical aspects of the differing drugs; particularly relating to adults with intellectual disability. Indeed the information available for the intellectual disabled population is limited to adults with Down syndrome. This review highlights the important pharmacological and clinical aspects of donepezil, rivastigmine, galantamine and memantine and supports the view that such drugs play an important part in the management of dementia in adults with intellectual disability. Future clinical and research issues are discussed. Copyright © 2004 John Wiley & Sons, Ltd.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Carbamates - therapeutic use</subject><subject>Cholinesterase Inhibitors - therapeutic use</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>dementia</subject><subject>donepezil</subject><subject>Down syndrome</subject><subject>Down Syndrome - complications</subject><subject>galantamine</subject><subject>Galantamine - therapeutic use</subject><subject>Geriatrics</subject><subject>Humans</subject><subject>Indans - therapeutic use</subject><subject>learning disability</subject><subject>Medical sciences</subject><subject>memantine</subject><subject>Memantine - therapeutic use</subject><subject>mental retardation</subject><subject>Neurology</subject><subject>Nootropic Agents - therapeutic use</subject><subject>Phenylcarbamates</subject><subject>Piperidines - therapeutic use</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Rivastigmine</subject><issn>0885-6230</issn><issn>1099-1166</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0stu1DAUBuAIgehQkHgC5A2XRQN2bnbYlQID0nArICQ21olzMuPiOMF2OkxfkNci6USFDYKFZR_7029LPlF0l9HHjNLkybr344Lza9GC0bKMGSuK69GCCpHHRZLSg-iW92eUjmdM3IwOWJ6wcfBF9PMUzzVuSdeQurPY44U2R8Tpc_BBr1tt8YiswYANMBUEbE1abMd6qprOkbBBEhxCaNGGyxycVhqItuTYXGxQt-geelJrj-Bx2oZ6MMGTrQ4b8rzbWuJ3tnZdi0-JbnujFQTdWX-Vr21AY1CFAcyUA5U2OuxI3_WDubS3oxsNGI935vkw-vzyxaeTV_Hq3fL1yfEqVjkteJwJRVEwEKJmGWaNKpNS1ZDmdVKJCoFlnDNUikFeMsXSsklVBQWkWcqxqFV6GD3Y5_au-z6gD7LVXo2PA4vd4GVRFFlKBf8nnD5AMM7-BzKWMTrCR3uoXOe9w0b2TrfgdpJRObWBHNtATm0w0ntz5lC1WP-G87-P4P4MwCswjQOrtP_DibxM82J08d5ttcHdXy-Uy_cf54tnr33AH1ce3DdZ8JTn8svbpfx6-ky8-bAqZZL-AodL3Us</recordid><startdate>200406</startdate><enddate>200406</enddate><creator>Prasher, V. P.</creator><general>John Wiley & Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>200406</creationdate><title>Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population</title><author>Prasher, V. P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5067-48c0e81a88d14e4fc929cda35d2b8bea14771ecc1a591c139f3cba6a3437e6dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Carbamates - therapeutic use</topic><topic>Cholinesterase Inhibitors - therapeutic use</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>dementia</topic><topic>donepezil</topic><topic>Down syndrome</topic><topic>Down Syndrome - complications</topic><topic>galantamine</topic><topic>Galantamine - therapeutic use</topic><topic>Geriatrics</topic><topic>Humans</topic><topic>Indans - therapeutic use</topic><topic>learning disability</topic><topic>Medical sciences</topic><topic>memantine</topic><topic>Memantine - therapeutic use</topic><topic>mental retardation</topic><topic>Neurology</topic><topic>Nootropic Agents - therapeutic use</topic><topic>Phenylcarbamates</topic><topic>Piperidines - therapeutic use</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Rivastigmine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prasher, V. P.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of geriatric psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prasher, V. P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population</atitle><jtitle>International journal of geriatric psychiatry</jtitle><addtitle>Int. J. Geriat. Psychiatry</addtitle><date>2004-06</date><risdate>2004</risdate><volume>19</volume><issue>6</issue><spage>509</spage><epage>515</epage><pages>509-515</pages><issn>0885-6230</issn><eissn>1099-1166</eissn><abstract>The management of dementia in Alzheimer's disease has dramatically changed since the development of anti‐dementia drugs. However, there is limited information available regarding the bio‐medical aspects of the differing drugs; particularly relating to adults with intellectual disability. Indeed the information available for the intellectual disabled population is limited to adults with Down syndrome. This review highlights the important pharmacological and clinical aspects of donepezil, rivastigmine, galantamine and memantine and supports the view that such drugs play an important part in the management of dementia in adults with intellectual disability. Future clinical and research issues are discussed. Copyright © 2004 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>15211527</pmid><doi>10.1002/gps.1077</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-6230 |
| ispartof | International journal of geriatric psychiatry, 2004-06, Vol.19 (6), p.509-515 |
| issn | 0885-6230 1099-1166 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66643087 |
| source | MEDLINE; Wiley Online Library |
| subjects | Alzheimer Disease - drug therapy Biological and medical sciences Carbamates - therapeutic use Cholinesterase Inhibitors - therapeutic use Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases dementia donepezil Down syndrome Down Syndrome - complications galantamine Galantamine - therapeutic use Geriatrics Humans Indans - therapeutic use learning disability Medical sciences memantine Memantine - therapeutic use mental retardation Neurology Nootropic Agents - therapeutic use Phenylcarbamates Piperidines - therapeutic use Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Rivastigmine |
| title | Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T19%3A32%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20of%20donepezil,%20rivastigmine,%20galantamine%20and%20memantine%20for%20the%20treatment%20of%20dementia%20in%20Alzheimer's%20disease%20in%20adults%20with%20Down%20syndrome:%20implications%20for%20the%20intellectual%20disability%20population&rft.jtitle=International%20journal%20of%20geriatric%20psychiatry&rft.au=Prasher,%20V.%20P.&rft.date=2004-06&rft.volume=19&rft.issue=6&rft.spage=509&rft.epage=515&rft.pages=509-515&rft.issn=0885-6230&rft.eissn=1099-1166&rft_id=info:doi/10.1002/gps.1077&rft_dat=%3Cproquest_cross%3E21111410%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21111410&rft_id=info:pmid/15211527&rfr_iscdi=true |